Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil vs butorphanol for oxytocin-related adverse reactions after cesarean section under spinal anesthesia
ChiCTR2500106829Phase 4Not yet recruiting
- Sponsor
- Jianyang People's Hospital
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remifentanil in None, postoperative nausea and vomiting (PONV) and Cardiovascular collapse (2 arms), sponsored by Jianyang People's Hospital. Primary endpoint: Incidence of nausea and vomiting. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
remifentanil
03
Conditions
postoperative nausea and vomiting (PONV)Cardiovascular collapse
Beyond the preview
Go deeper on ChiCTR2500106829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106829.